T45.695D Adverse effect of other fibrinolysis-affecting drugs, subsequent encounter

Name of the Condition

• Adverse effect of other fibrinolysis-affecting drugs, subsequent encounter (ICD-10 code: T45.695D)

Summary

This condition represents an adverse reaction to fibrinolysis-affecting drugs not classified elsewhere, occurring during a subsequent encounter for care. It includes harmful effects resulting from the use of these medications, which modulate the body's ability to dissolve blood clots. The "subsequent encounter" designation indicates ongoing care related to the adverse effect, rather than the initial episode.

Causes

Adverse effects may result from excessive dosing, drug interactions, or individual sensitivity to fibrinolysis-affecting agents. These outcomes can stem from medication errors, altered drug metabolism, or patient-specific factors. The "other" classification specifies drugs outside the thrombolytic class, such as certain plasminogen activators or fibrinolytic agents.

Risk Factors

• High doses or prolonged use of these medications.
• Concurrent use of other drugs that interact with fibrinolysis-affecting agents (e.g., anticoagulants).
• Pre-existing conditions affecting drug metabolism (e.g., liver or kidney impairment).
• Age-related changes in drug sensitivity (e.g., elderly or pediatric patients).
• History of bleeding disorders or prior adverse drug events.

Symptoms

• Excessive bleeding (e.g., bruising, hematomas, gastrointestinal bleeding).
• Uncontrolled bleeding from minor injuries.
• Hematuria or blood in urine.
• Epistaxis (nosebleeds).
• Petechiae or purpura (small red/purple spots on skin).
• Fatigue or weakness due to blood loss.

Diagnosis

Diagnosis involves clinical evaluation of symptoms, medication history, and laboratory tests to assess bleeding or clotting abnormalities. Healthcare providers may review dosing, drug interactions, and patient-specific factors. Imaging or other tests may be used to identify bleeding sites or complications.

Treatment Options

Treatment focuses on managing bleeding and discontinuing the causative drug. Interventions may include supportive care, blood transfusions, or administration of antidotes (e.g., tranexamic acid). Monitoring for complications and adjusting medications are key to recovery.

Prognosis and Follow-Up

Prognosis depends on the severity of bleeding, timely intervention, and underlying health. Most patients recover with appropriate management, but severe cases may require prolonged care. Follow-up includes monitoring for recurrence and adjusting treatment plans.

Complications

• Severe or life-threatening bleeding.
• Organ damage from uncontrolled hemorrhage.
• Anemia due to blood loss.
• Prolonged hospitalization.
• Need for surgical intervention.

Lifestyle & Prevention

• Adhere to prescribed dosing and avoid self-adjusting medications.
• Inform healthcare providers of all medications, including over-the-counter drugs.
• Report unusual bleeding or bruising promptly.
• Follow up regularly to monitor drug effects and adjust therapy as needed.

When to Seek Professional Help

Seek immediate medical attention for uncontrolled bleeding, severe bruising, or signs of internal hemorrhage (e.g., dizziness, fainting, blood in urine/stool). Contact a provider for persistent or worsening symptoms.

Tips for Medical Coders

Document the specific fibrinolysis-affecting drug involved, the nature of the adverse effect, and the encounter type (subsequent) to support accurate coding. Include details on treatment, complications, and follow-up to ensure comprehensive coding. Verify that the drug is classified as "other" (not a thrombolytic) to meet code specificity.